Blue Owl Capital Holdings’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Blue Owl Capital Holdings’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,500	Closed	-$375	–	94
2025 Q4	$375	Buy	+12,500	New	+$444	﹤0.01%	78
2024 Q4	–	Sell	-12,500	Closed	-$396	–	122
2024 Q3	$396	Buy	+12,500	New	+$724	﹤0.01%	123

Other funds holding SLXNW

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Blue Owl Capital Holdings's SLXNW Position: Q1 2026 in Review

Blue Owl Capital Holdings sold out of Silexion Therapeutics Warrant (SLXNW) in Q1 2026, closing a stake of 12,500 shares — an estimated $375 sold.

Blue Owl Capital Holdings first reported a position in SLXNW in Q3 2024 and held it in 2 quarters. The position peaked at $396 in Q3 2024. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

Blue Owl Capital Holdings reported no remaining Silexion Therapeutics Warrant position as of Q1 2026 after selling out during the quarter.
Blue Owl Capital Holdings sold 12,500 Silexion Therapeutics Warrant shares in Q1 2026, an estimated $375.
Blue Owl Capital Holdings first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 2 quarters.
Blue Owl Capital Holdings's Silexion Therapeutics Warrant position peaked at $396 in Q3 2024.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.